weekly biotechnology news wrap up

February 24, 2017

February 24, 2017

This week’s headlines include: BrainStorm seeks early approval for stem cell treatment in Canada, Gates Foundation boosts UCSD-led malaria research, Biosimilar Inflectra matches Remicade efficacy in trial, and New culture method boosts T cells’ ability to recognize multiple cancers.


“BrainStorm seeks early approval for stem cell treatment in Canada,” Reuters

“Israel’s BrainStorm Cell Therapeutics is seeking early approval in Canada for its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, even before it completes late-stage clinical trials….”

“Gates Foundation boosts UCSD-led malaria research,” The San Diego Union Tribune

“The Bill and Melinda Gates Foundation has awarded a $4.7 million supplemental grant to a UC San Diego-led research consortium to develop therapies to eradicate malaria. The 3-year grant is led by Elizabeth Winzeler, professor in the pediatric division of host-microbe systems and therapeutics at UCSD School of Medicine…”

“Biosimilar Inflectra matches Remicade efficacy in trial,” PharmaTimes

“Pfizer and Celltrion have unveiled Phase III study data comparable safety and efficacy between biosmilar Inflectra and reference drug Remicade in patients with moderate-to-severe Crohn’s disease (CD)…”

“New culture method boosts T cells’ ability to recognize multiple cancers,” Fierce Biotech

Engineered T cells, which aim to mount an immune response against cancer, are gaining steam in the immuno-oncology market, with Kite Pharma and Novartis racing to get their CAR-T therapies for blood cancers approved. But they don’t work for all patients, and researchers have struggled to find uses for them in solid tumors.

In Case You Missed It:

Cell Culture Dish


Downstream Column logo tall

Cell Culture Events:

Bioprocess International West – February 27-March 2, 2017, San Francisco

The BPI West 2017 agenda format is designed to break down silos across multiple departments that work in the same stage of development. With four concurrent tracks focused on early stage process development through commercial manufacturing, attendees can collectively share challenges and discuss the solutions needed to improve the speed, cost and quality of biologics development.

Cell Culture Dish Readers – Click to Get a free Exhibit Hall Pass!

Going to BPI West 2017? Don’t miss these great talks and activities!

World Vaccine Congress – April 10-12, 2017, Washington D.C.

The 17th Annual World Vaccine Congress is the place where the global vaccine industry meets to discuss commercial and scientific issues around regulation, strategy, manufacturing, trials, partnering, influenza, cancer, emerging diseases and veterinary vaccines.

Across 150 sessions, you will learn from leading experts across the issues most impacting on the wider vaccine sector, as well as delve into your specialist area of research and job focus in co-located conferences.

Meet over 700 of your peers in one room and take advantage of the multiple extended networking breaks, co-located World Vaccine Congress (including 7 streams on Immune Profiling, Cancer & Immunotherapy, Influenza & Respiratory, Clinical Trials, Emerging Diseases, Partnerships, Veterinary Vaccines and Bioprocessing & Manufacturing) as well as the evening drinks reception.

For more information, please visit the website https://goo.gl/nJ2bZ1


Continuous Bioprocessing Solutions: An Update on Significant Enabling Technology Advances – March 7, 2017

While continuous processing has been applied for several decades, the highly regulated biopharm industry has just started to embrace this approach. The team at Pall Life Sciences has leveraged an industry-leading single-use portfolio to deliver innovative continuous bioprocessing solutions to the market. Join our team as they detail the development journey, and highlight critical advances to date.